The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 130-143

  Tarasenko, Nataly ^a   Kessler Icekson, Gania ^a   Boer, Pnina ^a   Inbal, Aida ^a   Schlesinger, Hadassa ^a   Phillips, Don R ^b   Cutts, Suzanne M ^b   Nudelman, Abraham ^c   Rephaeli, Ada ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b LA TROBE UNIVERSITY   (Australia)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

Astrocytes; Cardiofibroblasts; Cardiomyocytes; Doxorubicin; HDAC inhibitor; HER2; Mammary carcinoma

Indexed keywords

AN 7; BUTYROYLOXYMETHYL DIETHYLPHOSPHATE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; HISTONE DEACETYLASE INHIBITOR; MYC PROTEIN; REACTIVE OXYGEN METABOLITE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANGIOGENIC PROTEINS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTES; BRAIN NEOPLASMS; BREAST NEOPLASMS; BUTYRIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; FIBROBLASTS; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFLAMMATION MEDIATORS; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MYOCYTES, CARDIAC; ORGANOPHOSPHORUS COMPOUNDS; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 84856556018     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9542-z     Document Type: Article

References (41)

1. Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30-37
2. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, Epstein JA, Gruber PJ (2008) Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 22:3549-3560
3. Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 10:32-42
4. Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958-3969
5. Rephaeli A, Zhuk R, Nudelman A (2000) Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications. Drug Dev Res 50:379-391
6. Blank-Porat D, Gruss-Fischer T, Tarasenko N, Malik Z, Nudelman A, Rephaeli A (2007) The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Lett 256:39-48 (Pubitemid 47333328)
7. Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass- Kogan D, Inbal A, Rephaeli A (2008) Histone deacetylase inhibitors: The anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis 25:703-716
8. Rephaeli A, Entin-Meer M, Angel D, Tarasenko N, Gruss-Fischer T, Bruachman I, Phillips DR, Cutts SM, Haas-Kogan D, Nudelman A (2006) The selectivity and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Investig New Drugs 24:383-392 (Pubitemid 43876074)
9. Chou TC (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideeout DC (eds) Synergism and antagonism in chemotherapy. Academic, New York, pp 66-102
10. Rephaeli A, Waks-Yona S, Nudelman A, Tarasenko I, Tarasenko N, Phillips DR, Cutts S, Kessler-Icekson G (2007) Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin induced cardiotoxicity. Br J Cancer 96:1667-1674 (Pubitemid 46847204)
11. Engel D, Nudelman A, Levovich I, Gruss-Fischer T, Rephaeli A (2006) Mode of interaction between the HDAC inhibitor AN-7 and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J Cancer Res Clin Oncol 132:673-683 (Pubitemid 44310333)
12. Nudelman A, Gnizi E, Katz Y, Azulai R, Cohen-Ohana M, Zhuk R, Sampson SR, Langzam L, Fibach E, Prus E, Pugach V, Rephaeli A (2001) Prodrugs of butyric acid (lll) novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem 36:63-74 (Pubitemid 32174854)
13. Shalitin N, Friedman M, Schlesinger H, Barhum Y, Levy MJ, Schaper W, Kessler-Icekson G (1996) The effect of angiotensin II on myosin heavy chain expression in cultured myocardial cells. In Vitro Cell Dev Biol Anim 32:573-578 (Pubitemid 26399201)
14. Murphy S (1990) Generation of astrocytes cultures from normal and neoplastic central nervous system. In: Conn P (ed) Methods in neurosciences, vol 2. Academic Press Inc, San Diego, pp 33-47
15. Rephaeli A, Gil-Ad I, Aharoni A, Tarasenko I, Tarasenko N, Geffen Y, Halbfinger E, Nisemblat Y, Weizman A, Nudelman A (2009) Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity. J Med Chem 52:3010-3017
16. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858-5868 (Pubitemid 28124064)
17. Shchors K, Evan G (2007) Tumor angiogenesis: Cause or consequence of cancer? Cancer Res 67:7059-7061 (Pubitemid 47206529)
18. Bikfalvi A, Klein S, Pintucci G (1997) Biological roles fibroblast growth factor-2. Endocr Rev 18:26-45 (Pubitemid 27076454)
19. Lin CW, Shen SC, Hou WC, Yang LY, Chen YC (2008) Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol Cancer Ther 7:1195-1206
20. Koneru S, Penumathsa SV, Thirunavukkarasu M, Vidavalur R, Zhan L, Singal PK, Engelman RM, Das DK, Maulik N (2008) Sidenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: Role of VEGF/ angiopoietin-1. J Cell Mol Med 12:265-2664
21. Mito S, Ozono R, Oshima T, Yano Y, Watari Y, Yamamoto Y, Brydun A, Igarashi K, Yoshizumi M (2008) Myocardial protection against pressure overload in mice lacking Bach1, a transcriptional repressor of heme-oxygenase-1. Hypertension 51:1570-1577
22. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624-6628
23. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M (1997) A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER-2 blocks crosstalk with growth factor receptors. Oncogene 14:2099-2109 (Pubitemid 27237013)
24. Dubois NC, Adolphe C, Ehninger A, Wang RA, Robertson EJ, Trumpp A (2008) Placental rescue reveals a sole requirement for c-Myc in embryonic erythroblast survival and hematopoietic stem cell function. Development 135:2455-2465
25. Kim J-W, Gao P, Liu Y-C, Semenza GL, Dang CV (2007) Hypoxia-Inducible Factor 1 and dysregulated c-Myc cooperatively induce Vascular Endothelial Growth Factor and metabolic switches hexokinase 2 and pyruvate dehydrogenese kinase 1. Mol Cell Biol 27:7381-7393 (Pubitemid 350033646)
26. Ements LA, Davidson NE (2003) The follow-up of breast cancer. Semin Oncol 30:338-348 (Pubitemid 36706558)
27. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW (2009) Management of cardiac health in trastuzumab- treated patients with breast cancer: Updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100:684-692
28. Zhao L, Eghbali-Webb M (2001) Release pro- and anti-angiogenic factors by human cardiac fibroblasts: Effects on DNA synthesis and protection under hypoxia in human endothelial cells. Biochim Biophys Acta 1538:273-282 (Pubitemid 32402250)
29. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D (2005) NAD(P)H Oxidase 4 mediates Transforming growth factor-β1-indued differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97:900-907 (Pubitemid 41552675)
30. Diwan A, Tran T, Misra A, Mann DL (2003) Inflammatory mediators and the failing heart: A translational approach. Curr Mol Med 3:161-182 (Pubitemid 36285104)
31. Vanlangenakker N, Berghe TV, Krysko DV, Festjens N, Vandenabeele P (2008) Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 8:207-220 (Pubitemid 351982539)
32. Hori M, Nishida K (2009) Oxidative stress and left ventricular remodeling after myocardial infarction. Cardiovasc Res 81:457-464
33. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 35:839-843 (Pubitemid 40839736)
34. Margosio B, Rusnati M, Bonezzi K, Cordes BA, Annis D, Urbanati C, Givazzi R, Presta M, Ribatti D, Mosher DF, Taraboletti G (2008) Fibroblast growth factor-2 binding to the trombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 40:700-709 (Pubitemid 351288589)
35. Vita M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Canc Biol 16:318-330 (Pubitemid 44311040)
36. Virag JAI, Rolle ML, Reece J, Hardouin S, Feigl EO, Murry CE (2007) Fibroblast growth factor-2 regulates myocardial infarct repair. Effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 171:1431-1440 (Pubitemid 350158305)
37. Gueron G, Siervi AD, Ferrando M, Salerno M, Luca PD, Elguero B, Meiss R, Navone N, Vazquez ES (2009) Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res 7:1745-1755
38. Otterbein LE, Bach FH, Alam J, Soares M, Lu HT, Wysk M, Davis RJ, Flavell RA, Choi AM (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6:422-428 (Pubitemid 30208159)
39. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043-1046 (Pubitemid 17049750)
40. Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, AA FIII, Kukreja RC (2005) HIF-1 activation postischemic myocardial injury: Role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol 289: H542-H548 (Pubitemid 41129367)
41. Losordo DW, Demmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part 1: Angiogenic cytokines. Circulation 109:2487-2491 (Pubitemid 38720544)